Robert Bell, a venture partner at Intersouth, is a member of the expanded scientific advisory board at KAI Pharmaceuticals.

Bell was a founder of Sphinx Pharmaceuticals and a former vice president of research at Glaxo Wellcome before joining Intersouth. He ha also taught at Duke University.

KAI, which is based in San Francisco, added eight people to the board. KAI is pursuing development of drugs for treatment of acute cardiovascular disease and other disorders.